A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

2期已完成 NCT05258071

适应症	Parkinson Disease
分期	2期
申办方	Integrative Research Laboratories AB
状态	已完成
受试者人数	104 人
干预（药物）	Pirepemat
开始日期	2022年6月15日
完成日期	2024年12月4日
结果公布日	2026年7月9日

摘要

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.

Baseline to end of full dose treatment (up to Day 84). · % of baseline fall rate

Pirepemat 300 mg	76.9 ± 72.05 % of baseline fall rate
Pirepemat 600 mg	64.5 ± 49.18 % of baseline fall rate
Placebo	68.9 ± 90.22 % of baseline fall rate

p-value	0.5753
Median ratio	0.973 (95% CI 0.706–1.274)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers — Rutgers, The State University of New Jersey
Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский